Search results
Results from the WOW.Com Content Network
Oligonucleotides are characterized by the sequence of nucleotide residues that make up the entire molecule. The length of the oligonucleotide is usually denoted by "-mer" (from Greek meros, "part"). For example, an oligonucleotide of six nucleotides (nt) is a hexamer, while one of 25 nt would usually be called a "25-mer".
Many oligonucleotide synthesis factories designed and manufactured their own custom platforms and little is known due to the designs being proprietary. The VLSS design continued to be refined and is continued in the QMaster synthesizer [105] which is a scaled down platform providing milligram to gram amounts of synthetic oligonucleotide.
In a similar manner to antibody therapeutics, Optimer therapeutics can be used as direct agonists or antagonists for the development of novel therapeutic moieties. [16] Additionally, Optimers can be used as conjugates for the targeted delivery of a range of drug cargo, such as chemotherapeutics , [ 14 ] gene silencing therapeutics, [ 22 ] and ...
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
BC-007, whose international nonproprietary name is Rovunaptabin, [1] is an oligonucleotide aptamer, a synthetic DNA compound designed to bind other chemicals. [2] BC-007 is in early-stage clinical trials as a lead compound intended for the potential treatment of heart failure or long COVID .
Synthetic oligonucleotides are used in various molecular biology applications, e.g., polymerase chain reaction (PCR), molecular beacons, microarrays, mutagenesis, RNAi, antisense and gene synthesis. Published bioinformatics algorithms can predict biophysical properties of oligonucleotides from their sequence and estimate oligonucleotide ...
In 2010, synthetic nucleases called transcription activator-like effector nucleases (TALENs) provided an easier way to target a double-stranded break to a specific location on the DNA strand. Both zinc finger nucleases and TALENs require the design and creation of a custom protein for each targeted DNA sequence, which is a much more difficult ...
In April of 2018, the Arcturus Therapeutics board of directors at the time filed their own complaint against Joseph Payne and his nominees to the board. [10] In May of 2018, a legal settlement was agreed upon: 4 new directors were appointed to the board (Peter Farrell, Andrew Sassine, James Barlow and Magda Marquet) resulting in the resignation ...